

## DAFTAR PUSTAKA

- A. Angbalaga, C. C. Ani, D. Atsukwei, E. D. Eze, A. M. Afodun, E. O. Igoh, S. C. Owoeye and C. B. Ukaonu (2018). Correlation of hepatobiliary ultrasonographic findings with cd4 cell count and liver enzymes in adult hiv/aids patients in Jos. *Journal of AIDS and HIV Research*, 10(6), 83–95.
- Agustya, M., Wesnawa, D. P., Nama, N., Bagian, P., Smf, /, & Buleleng, P. R. (2016). *Profil Pasien Koinfeksi TB – HIV*. *J Respir Indo*, 36(3), 175–181
- Bayupurnama. (2014). *Hepatotoksisitas imbas obat. Dalam Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S (eds). Buku ajar ilmu penyakit dalam jilid II*. Jakarta : Pusat Penerbitan Departemen Ilmu Penyakit Dalam FK UI.
- Boyer TD, M. M. & S. A. (2012). *Zakim and Boyer's Hepatology A Text Book of Liver Disease* (6th ed). Philadelphia: Elsevier saunders.
- Clarasanti, I., Wongkar, M. C. P., & Waleleng, B. J. (2016). Gambaran enzim transaminase pada pasien tuberkulosis paru yang diterapi dengan obat-obat anti tuberkulosis di RSUP Prof. Dr. R. D. Kandou Manado. *E-CliniC*, 4(1), 1–6.
- Delita Prihatni, Ida Parwati, Idaningroem Sjahid, C. R. (2005). Efek Hepatotoksik Anti Tuberkulosis Terhadap Kadar Aspartate Aminotransferase Dan Alanine Aminotransferase Serum Penderita Tuberkulosis Paru. *Indonesian Journal of Clinical Pathology and*

*Medical Laboratory*, 12(1), 1–5.

Ditjen PPM & PL. (2014). *Pedoman Nasional Pengendalian Tuberkulosis 2014*. Jakarta : Kementrian Kesehatan Republik Indonesia.

Ditjen PPM & PL Depkes. (2016). *Profil Kesehatan Indonesia tahun 2015*. Jakarta : Kementrian Kesehatan Republik Indonesia.

Dyah Nova Ranti Ayuningtyas, A. (2013). *Perbedaan Kadar SGOT-SGPT Sebelum Dan Sesudah Pemberian Obat Antituberkulosis Fase Awal*. Jurnal Fakultas Kedokteran dan Ilmu Kesehatan Universitas Muhammadiyah Yogyakarta.

Hall, P., & Cash, J. (2012). *What is the real function of the liver “function” tests?: Discovery Service for Endeavour College of Natural Health Library*. *Ulster Medical Journal*, 81(1), 30–36.

Jang, E. S., Jeong, S. H., Hwang, S. H., Kim, H. Y., Ahn, S. Y., Lee, J., Lee, S. H., Park, Y. S., Hwang, J. H., Kim, J. W., Kim, N., & Lee, D. H. (2012). *Effects of coffee, smoking, and alcohol on liver function tests: A comprehensive cross-sectional study*. *BMC Gastroenterology*, 12(1), 1.

Juliarta, I. G., Mulyantari, N. K., & I wayan Putu Sutirta Yasa. (2018). *Gambaran Hepatotoksisitas ( ALT / AST ) Penggunaan Obat AntiTuberkulosis Lini Pertama Dalam Pengobatan Pasien Tuberkulosis Paru Rawat Inap Di RSUP Sanglah Denpasar Tahun 2014*. *E\_Jurnal Medika*, 7(10).

- Kim JH, Nam WS, Kim SJ, Kwon OK Seung EJ, J. J. (2017). Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice. *Int J Mol Sci*, 18, 1–13.
- Lewis JH & Kleiner DE. (2012). *Hepatic injury due to drugs, herbal compounds, chemicals and toxins, Dalam: MacSween's Pathology of the Liver* Philadelphia : Elsvier.
- Loho IM, H. I. (2014). *Drug-induced liver injury – tantangan dalam diagnosis*. Jurnal CKD, 41(1).
- Maria I L, H. I. (2014). *Drug-induced liver injury – Tantangan dalam diagnosis*. Jakarta : Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia.
- Metushi I, Uetrecht J, P. E. (2016). Mechanism of isoniazid-induced hepatotoxicity: then and now. *Br J Clin Pharmacol*, 81, 1030–1036.
- National Institute of Diabetes and Digestive and Kidney Diseases. (2012). Severity Grading In Drug Induced Liver Injury. In *LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*. National Institute of Diabetes and Digestive and Kidney Diseases. <https://www.ncbi.nlm.nih.gov/books/NBK548241/> diperoleh 2 juli 2021
- Ngouleun, W., Biapa Nya, P. C., Pieme, A. C., & Telefo, P. B. (2016). Risk assessment of hepatotoxicity among tuberculosis and human immunodeficiency virus/AIDS-coinfected patients under tuberculosis treatment. *International Journal of Mycobacteriology*, 5(4), 482–488.

- Pingzheng, M., Zhu, Q., Teter, C., Yang, R., Deng, L., Yan, Y., Chen, J., Zeng, J., & Gui, X. en. (2014). Prevalence, drug-induced hepatotoxicity, and mortality among patients multi-infected with HIV, tuberculosis, and hepatitis virus. *International Journal of Infectious Diseases*, 28, e95–e100.
- Pranata, J. R., Mariadi, I. K., & Somayana, G. (2019). Prevalensi dan Gambaran Umum Drug-Induced Liver Injury Akibat Obat Anti Tuberkulosis pada Pasien Tuberkulosis di RSUP Sanglah Denpasar Periode Agustus 2016 – Juli 2017. *Jurnal Medika Udayana*, 8(9).
- Ramappa, Vidyasagar, Aithal, G. P. (2013). Hepatotoxicity Related to Anti-tuberculosis Drugs : Mechanisme and Management. *Journal of Physiology and Pharmacology*, 3(1), 37–49.
- Reza & Rachmawati. (2017). *Perbedaan Kadar Sgot Dan Sgpt Antara Subyek Dengan Dan Tanpa Diabetes Mellitus*. 6(2), 158–166.
- Rosida, A. (2016). *Pemeriksaan Laboratorium Penyakit Hati*. Berkala Kedokteran, 12(1), 123.
- Rusmini, H., Nurmalasari, Y., & Ariza, R. (2018). *Perbandingan Status Gizi Tb Luluh Paru Dengan Pasien Tb Tanpa Luluh Paru*. Jurnal Ilmu Kedokteran Dan Kesehatan, 5, 38–43.
- Sarkar S, Ganguly A, S. H. (2016). Current overview of Anti-tuberculosis Drugs: Metabolism and Toxicities. *Mycobact Dis*, 6, 1–6.

Saukkonen, J. J., Cohn, D. L., Jasmer, R. M., Schenker, S., Jereb, J. A., Nolan, C. M., Peloquin, C. A., Gordin, F. M., Nunes, D., Strader, D. B., Bernardo, J., Venkataramanan, R., & Sterling, T. R. (2006). An official ATS statement: Hepatotoxicity of antituberculosis therapy. *American Journal of Respiratory and Critical Care Medicine*, 174(8), 935–952.

Shih TY, Pai CY, Yang P, Chang WL Wang NC, Y.-P. O. (2013). A novel mechanism underlies the hepatotoxicity of pyrazinamide. *Antimicrobial Agents and Chemotherapy*, 57, 1685–1690.

Sugiyono. (2007). *Metode Penelitian Kuantitatif Kualitatif dan R&D*. Bandung : Alfabeta.

Sumantri, A. F., Djumhana, A., Wisaksana, R., & Sumantri, R. (2015). *Insidensi dan Karakteristik Hepatotoksisitas Obat Antituberkulosis pada Penderita Tuberkulosis dengan dan tanpa Infeksi HIV*. *Global Medical & Health Communication (GMHC)*, 3(2), 78.

UNAIDS. (2016). *Global AIDS Update 2016*. Geneva : Joint United Nations Programme on HIV/AIDS.

Vitarani Dwi Ananda Nigrum, Arina Megasari, D. H. (2010). *Hepatotoksik pada pengobatan Tuberkulosis di RSUD tangerang-indonesia*. *Jurnal Ilmu Farmasi*, 7(1).

Wang P, Pradhan K, Zhong XB, M. X. (2016). Isoniazid metabolism and hepatotoxicity. *Acta Pharm Sin B*, 6, 384–392.

WHO. (2010). *Treatment of Extrapulmonary TB and TB in Special Situation*.

World Health Organization.

Wondwossen Abera, Cheneke, W., & Abebe, G. (2016). Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study. *International Journal of Mycobacteriology*, 5(1), 14–20.

Wright GD. (2012). Back to the future: a new 'old' lead for tuberculosis. *EMBO Molecular Medicine*, 4, 1029–1031.

Yimer, G., Aderaye, G., Amogne, W., Makonnen, E., Aklillu, E., Lindquist, L., Yamuah, L., Feleke, B., & Aseffa, A. (2008). *Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients*. PLoS ONE, 3(3), 1–5.

Zelege, A., Misiker, B., & Yesuf, T. A. (2020). *Drug-induced hepatotoxicity among TB/HIV co-infected patients in a referral hospital, Ethiopia*. BMC Research Notes, 13(1), 1–5.

Zulkifli amin, Djoerban, Z., Yunihastuti, E., Uyainah, A., & Zulkifli. (2013). *Profil Pasien Tb-hiv dan Non Tb-hiv di Rscm*. Indonesian Bulletin of Health Research, 41(4), 195–199